NOTE: The recording of this webinar will be available shortly.
Primary cell lines and 3D model systems can provide in vitro assays of high physiological relevance, but the availability of cells and/or suitable assay technologies limit their application to large scale screening. The use of differentiated stem cells provides a disease- and tissue type-relevant alternative, particularly for investigating disease indications where there is a clear genetic causal link.
View this webinar to learn how human embryonic stem cells were used to develop and validate a 384-well format assay and subsequently conduct a high-throughput screen to identify compounds that modulate mutant protein levels in a neurodegenerative disease, demonstrating how stem cells balance biological relevance and throughput.
- David Cronk, CBiol, MRSB, Director, High-Throughput Screening Services, Charles River
- Bethany Nancolas, PhD, Senior Scientist, Biology, Charles River